Matching trials
1,853 results
- Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691): Complete Statistical AnalysisIndependent statistical analysis of Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691): primary endpoint results, effect estimate with confidence…
- FLAMEIndependent statistical analysis of the FLAME phase 3 trial of QVA149 versus LABA/ICS in COPD, including exacerbation rates, time-to-event analyses, non-inferiority methodology, safety, and statistical interpretation.
- FLAMEComplete statistical analysis of the FLAME phase 3 trial of fluorometholone 0.1% ophthalmic suspension as adjunctive therapy after trichiasis surgery, including trial design, registered endpoints, statistical methods, reported results, safety, and interpretation.
- FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides): Complete Statistical AnalysisIndependent statistical analysis of FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides): primary endpoint results, effect estimate with confidence…
- FLAURA2Independent statistical analysis of FLAURA2, the randomized phase 3 trial of osimertinib with chemotherapy versus osimertinib alone in first-line treatment of EGFR-mutated non-small cell lung cancer. Includes trial design, endpoints, survival analyses,…
- FLAXPADIndependent statistical analysis of Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- FLEX MIndependent statistical analysis of A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- FLEX VIndependent statistical analysis of A Study in Participants With Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01202773).
- FLOREYIndependent statistical analysis of Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- FLOT4An independent statistical analysis of FLOT4 (NCT01216644), evaluating FLOT versus ECF in patients with locally advanced, resectable gastric cancer. Includes trial design, endpoints, statistical methodology, and interpretation.
- FLOWIndependent statistical analysis of the FLOW phase 3 trial of semaglutide versus placebo in people with type 2 diabetes and chronic kidney disease, including trial design, the composite renal endpoint, Cox proportional-hazards…
- FLOWIndependent statistical analysis of A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease: primary endpoint results, effect estimate with confidence…
- FLUBUTBIIndependent statistical analysis of Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01366612).
- Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight: Complete Statistical AnalysisIndependent statistical analysis of Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Fluticasone Nasal Spray Patient Preference Study: Complete Statistical AnalysisIndependent statistical analysis of Fluticasone Nasal Spray Patient Preference Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00398476).
- Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT): Complete Statistical AnalysisIndependent statistical analysis of Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00135811).
- FOCUSComplete statistical analysis of the FOCUS randomized phase 3 trial comparing liberal and restrictive blood transfusion strategies in surgical patients with cardiovascular disease, including endpoint definitions, reported odds ratios and risk differences,…
- FOCUSIndependent statistical analysis of A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- FOCUSIndependent statistical analysis of An Efficacy and Safety Study of Fremanezumab in Adults With Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- FORTRESSIndependent statistical analysis of Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- FOURIER-OLEAn independent statistical analysis and educational interpretation of FOURIER-OLE, a phase 3 open-label extension study of evolocumab in participants with dyslipidemia.
- FREEDOMIndependent statistical analysis of the FREEDOM trial comparing coronary artery bypass grafting with percutaneous coronary intervention in individuals with diabetes and multivessel coronary artery disease, including time-to-event methods, reported results, safety, and…
- FREEDOMSIndependent statistical analysis of the FREEDOMS phase 3 trial of fingolimod in relapsing-remitting multiple sclerosis, covering randomized design, annualized relapse rate, statistical methodology, safety, and interpretation.
- FREEDOMS IIIndependent statistical analysis of Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- FRESCOAn independent statistical analysis of the phase 3 FRESCO trial of fruquintinib versus placebo in patients with colorectal cancer. Includes trial design, the registered overall-survival endpoint, statistical methodology, planned analysis, and interpretation.
- FRESCO-2Independent statistical analysis of the phase 3 FRESCO-2 trial of fruquintinib plus best supportive care versus placebo plus best supportive care in metastatic colorectal cancer, including overall survival, progression-free survival, response, statistical…
- FRONTIERIndependent statistical analysis of Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole: Complete Statistical AnalysisIndependent statistical analysis of Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00543127).
- G-BMTIndependent statistical analysis of Buprenorphine Group Medical Visits in Primary Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02526212).
- Gabapentin for Post-Operative Pain Control and Narcotic Reduction in Scrotal Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin for Post-Operative Pain Control and Narcotic Reduction in Scrotal Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00880191).
- GALAComplete statistical analysis of the phase 3 GALA trial of glatiramer acetate 40 mg three times weekly versus placebo in relapsing-remitting multiple sclerosis, including trial design, relapse endpoints, MRI outcomes, statistical methodology,…
- GALACTIC-HFIndependent statistical analysis of GALACTIC-HF, the randomized phase 3 trial of omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, including time-to-event methods, KCCQ analysis, confidence intervals, multiplicity, and safety.
- GALATHEAIndependent statistical analysis of the phase 3 GALATHEA trial of benralizumab 30 mg and 100 mg versus placebo in moderate to very severe COPD with exacerbation history, covering negative binomial exacerbation-rate ratios,…
- Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03803475).
- GAVOTTEIndependent statistical analysis of A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS): primary endpoint results, effect…
- GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD): Complete Statistical AnalysisIndependent statistical analysis of GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GDX-44-016Independent statistical analysis of Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06057168).
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval,…
- GEMINI LTSIndependent statistical analysis of An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- GEMINI Study – A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection: Complete Statistical AnalysisIndependent statistical analysis of GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3: Complete Statistical AnalysisIndependent statistical analysis of Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00878969).
- Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury: Complete Statistical AnalysisIndependent statistical analysis of Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- GeparSixtoIndependent statistical analysis of GeparSixto (NCT01426880), a randomized phase 2/3 trial evaluating addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer.
- GETGOAL-L-ASIAIndependent statistical analysis of GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA): primary endpoint results, effect…
- GETGOAL-MONOIndependent statistical analysis of GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- GLEAMIndependent statistical analysis of A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME): primary endpoint results, effect estimate with confidence…
- GLITTER 2Independent statistical analysis of Gan & Lee Insulin Glargine Target Type (2) Evaluating Research: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03371108).